Learning Objectives

Upon completion of the activity, participants should be able to:

Discuss Updated Guidelines and Management of Persistent and Recurrent Hyperparathyroidism
Quantify racial differences in osteoporosis and fragility fractures.
Evaluate and manage transplant related bone disorders
Discuss approaches in screening and diagnosis of low bone density in transgender people
Discuss physiology and pathophysiology and the utility of antibodies directed against fibroblast growth factor 23

Accreditation

Target Audience

This educational initiative is intended for Endocrinologists.

Accreditation Statement

The American College of Endocrinology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American College of Endocrinology designates this enduring activity for a maximum of 5.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.75 MOC Medical Knowledge point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Disclosures/Conflicts of Interest

Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, The American Association of Clinical Endocrinology (AACE) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. AACE resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, AACE seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. AACE is committed to providing learners with high-quality CME.

Activity Staff Disclosures

The planners, reviewers, editors, staff, CME committee, and other members at the American Association of Clinical Endocrinology who control content have no relevant financial relationships to disclose.

Faculty Disclosures

First	MI	Last	Credentials	Position	Institution	Role	Disclosure(s)
Robert	A.	Wermers	MD, FACE	Professor of Medicine Mayo Clinic College of Medicine and Consultant and Chair Division of Endocrinology, Diabetes, Metabolism and Nutrition Mayo Clinic Rochester	Mayo Clinic College of Medicine; Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic	Speaker	Nothing to disclose
Jad		Sfeir	MD, MS, FACP	Assistant Professor of Medicine	Mayo Clinic	Speaker	Nothing to disclose
Nicole	C.	Wright	PhD, MPH	Associate Professor	University of Alabama at Birmingham	Speaker	Nothing to disclose
Gina		Woods	MD	Associate Clinical Professor	University of California, San Diego	Moderator	Nothing to disclose
Ejigayehu	G.	Abate	MD	Clinical Endocrinologist	Mayo Clinic Florida	Speaker	() :
Jennifer		Kelly	DO, FACE, CCD	Endocrinologist	University of Vermont Medical Center	Moderator	Nothing to disclose
Vin		Tangpricha	MD, PhD, FACE	Professor of Medicine	Emory University School of Medicine	Speaker	Nothing to disclose
Albert		Shieh	MD		University of California, Los Angeles	Speaker	Nothing to disclose

Disclosure of Unlabeled Use

AACE requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. AACE does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Disclaimer

The American Association of Clinical presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The American Association of Clinical Endocrinology assumes no liability for the information herein.

Summary


Availability:	On-Demand
	Expires on Jul 21, 2023


Cost:	Member: $172.50 Non-Member: $287.50

Credit Offered:

5.75 CME Credits

5.75 ABIM-MOC Points